



ASX ANNOUNCEMENT

29 April 2026

Capital Consolidation Complete

Sydney, Australia, 29 April 2026: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, advises that the consolidation of the Company's issued capital on a 1 for 100 basis, as set out in the Notice of Extraordinary General Meeting dated 19 March 2026 and approved by shareholders at the Meeting on 17 April 2026, is now complete.

The Company's post consolidation capital structure is set out below:

ASX code	Description	Number on issue	
Quoted securities		Pre-consolidation	Post consolidation
CHM	ORDINARY FULLY PAID	4,418,703,619	44,187,956
Unquoted securities			
CHMAY	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	303,254,331	3,032,569
CHMAAH	OPTION EXPIRING 10-OCT-2028 EX \$0.80*	25,000,000	250,000
CHMAAB	PERFORMANCE RIGHTS	7,227,904	72,280

** Option exercise price shown post consolidation*

New holding statements will be dispatched to security holders advising them of their securities held on a post consolidation basis. Normal trading of securities on a post consolidation basis will commence on 1 May 2026.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Contact

Investors

Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au